Doctor insights on:
Abraxane And Avastin
Yes it is an option: The standard therapy for ovarian cancer initially is still a taxane (usually Taxol) and Carboplatin. However, Abraxane is an effective taxane down the line for recurrences, and is potentially less toxic. Avastin (bevacizumab) has been combined safely with Abraxane and the two may be helpful for recurrence management. But the question is a bit difficult to answer concretely because circumstances differ. ...Read more
I am on Abraxane. Tumor Markers started climbing after two months. Dr. Wants to add Avastin (bevacizumab). Is this a good option? Mets to abdomen, bones & Liver.
Not a good idea: Rising tumor markers often predict tumor progression. But this is soft evidence. A more definitive way to confirm lack of response(progression) is by means of repeating Imaging studies(like X-rays/CT scan or PET scan) and compare them with prior study. If the tumor size has increased, then Abraxane is no longer useful for you. Treatment should be changed . Adding Avastin (bevacizumab) would not help the situati ...Read more
Avoid it, if it is p: Avastin (bevacizumab) causes interference in wound healing. So it is best to stop Avastin (bevacizumab) if you need to undergo surgery. It takes 4 to 6 weeks for the Avastin (bevacizumab) effects to go away after the last dose used.. Then it is safer to do surgery. Your oncologist as well as your surgeon can/will guide you in this regard, if you have not already been told about it. ...Read more
Stops angiogenesis : Avastin (bevacizumab), and was the first commercially available angiogenesis inhibitor. Its main action is the inhibition of the function of a natural protein called vascular endothelial growth factor (vegf) that stimulates new blood vessel formation. Because most malignant tumors are highly dependant on angiogenesis to obtain a blood supply and nutrients Avastin can stop or delay growth. ...Read moreSee 1 more doctor answer
Yes: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607001.html.Get a more detailed answer ›